Reduced-intensity conditioning (RIC) regimens for allogeneic haematopoietic @entity8 ( @entity8 ) have been shown to lead to engraftment of donor stem cells without the severe extra-haematological @entity137 of traditional myeloablative transplants. Between December 1998 and December 2000, 76 @entity1 underwent a RIC peripheral blood @entity8 in a prospective multicentre study. The median age was 53 years, and 57 @entity1 were beyond the early phase of their disease. The conditioning regimens consisted of @entity3118 (150 mg/m2) plus melphalan (140 mg/m2) or @entity1863 (10 mg/kg). @entity2132 ( @entity2132 ) prophylaxis consisted of @entity205 plus short-course @entity1499 . The preparative regimens were well tolerated. All @entity1 experienced severe @entity3043 , but haematological recovery was prompt in all but two cases (early deaths). The 100-d probability of developing grade II-IV acute @entity2132 was 32% (10% grade III-IV), and the 1-year probability of developing chronic extensive @entity2132 was 43%. Early complete donor chimaerism was observed in 52/68 @entity1 , and 16 evaluable @entity1 were in complete chimaerism 1 year post transplant. With a median follow-up of 283 d (355 in 48 survivors), the 1-year probability of transplant-related mortality was 20%, and the 1-year overall and progression-free survivals were 60% and 55% respectively. In conclusion, RIC regimens lead to low early @entity137 after allografting, with stable donor haematopoietic engraftment, with an apparent low risk of acute @entity2132 . @entity2132 , however, develops in a significant proportion of @entity1 .

Allogeneic peripheral blood XXXX with reduced-intensity conditioning: results of a prospective multicentre study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['SCT', 'stem cell transplantation'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity3118 :: ('MESH:C024352', 'Chemical') :: ['fludarabine'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporin A'] @entity2132 :: ('MESH:D006086', 'Disease') :: ['GVHD', 'Chronic GVHD', 'Graft-versus-host disease'] @entity1863 :: ('MESH:D002066', 'Chemical') :: ['busulphan'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate'] @entity3043 :: ('MESH:D010198', 'Disease') :: ['pancytopenia']
@entity8 :: (MESH:D007674,Disease) :: ['stem cell transplantation']
